Myeloproliferative Disorders Drugs Market Size, Share | Report 2031
Myeloproliferative Disorders Drugs Market Size, Share | Report 2031
Segments - Myeloproliferative Disorders Drugs Market by Indications (Ph+ Chronic Myelogenous Leukemia and Ph- Myeloproliferative Neoplasms [Myelofibrosis, Polycythemia Vera, and Essential Thrombocythemia]) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
Upcoming
| Report ID :HC-1931
| 4.8 Rating
| 70 Reviews
| 215 Pages
| Format :
Report Description
Myeloproliferative Disorders Drugs Market Outlook 2031
The global myeloproliferative disorders drugs market size was valued at USD 8.69 Billion in 2022 and is anticipated to reach USD 11.74 Billion by 2031, expanding at a CAGR of 3.4% during the forecast period, 2023 – 2031. The growth of the market is attributed to the increased awareness of myeloproliferative disorders worldwide as well as early diagnosis along with the rise in focus on research and development activities by key players.
Hematological abnormalities of the bone marrow and blood cells are known as myeloproliferative disorders. It occurs when scar tissue builds up inside the bone marrow, resulting in inadequate blood cell production. The existing medications are not sufficient for disease-modifying activity and they are still inadequate for addressing significant unmet requirements such as preventing haematological progression and reducing cardiovascular consequences.
Rising unmet market needs present a significant opportunity to produce ground-breaking first-in-class medicines and provide effective future therapy landscape for myeloproliferative diseases. Despite the market low growth, several firms are continuing to evaluate novel therapeutic techniques and combination regimens that could potentially improve treatment outcomes.
Myeloproliferative Disorders Drugs Market Trends, Drivers, Restraints, and Opportunities
- Rising incidence of myeloproliferative disorders as a result of the ageing population as well as changing lifestyles are propelling the market growth.
- Growing inclination towards early diagnosis of the disorders among a large number of health-conscious population are expected to boost the market growth during the forecast period.
- Increasing focus in research and development activities by key players is anticipated to spur the market growth in the coming years.
- Rising public awareness regarding the existing treatment facilities is anticipated to fuel the market expansion in the near future.
- Complicated reimbursement and multiple patent expirations are estimated to hamper the market growth.
Scope of Myeloproliferative Disorders Drugs Market Report
The report on the global myeloproliferative disorders market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Myeloproliferative Disorders Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Indications (Ph+ Chronic Myelogenous Leukemia and Ph- Myeloproliferative Neoplasms [Myelofibrosis, Polycythemia Vera, and Essential Thrombocythemia]) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Novartis AG; Bristol-Myers Squibb Company; Pfizer Inc.; Takeda Pharmaceutical Company Limited; Incyte Corporation; and Teva Pharmaceutical Industries Ltd. |
Myeloproliferative Disorders Drugs Market Segment Insights
The Polycythemia Vera segment is projected to account for a major market share
Based on indications, the myeloproliferative disorders market is bifurcated into Ph+ chronic myelogenous leukemia (CML) and Ph- myeloproliferative neoplasms (MPNs). The MPNs segment is further divided into myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET).
The polycythemia vera segment is expected to account for a key share of the market in the coming years owing to wide prevalence of myeloproliferative diseases in North America and Western Europe, with the lowest prevalence in East Asia.
MPNs are most commonly diagnosed in persons over the age of 60; however, the disease can strike anyone at any age. Primary myelofibrosis (PMF) and myelofibrosis transformation from preceding polycythemia vera (post-PV MF) or essential thrombocytosis are all types of myelofibrosis (post-ET MF). Polycythemia vera (PV) is a condition in which red blood cells proliferate constantly.
An increase in hemoglobin causes an increase in blood volume and viscosity, as well as an increased risk of thrombosis. A rise in platelet count and a proclivity for vascular occlusive events and bleeding describe essential thrombocythemia (ET). CML is a myeloproliferative neoplasm marked by uncontrolled granulocyte proliferation and the presence of the BCR-ABL1 fusion gene on the Philadelphia chromosome.
Regional Analysis
On the basis of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Europe is anticipated to dominate the market by exhibiting an impressive CAGR during the forecast period.
The presence of a large targeted population, many product launches, and increased adoption of innovative therapies by a large number of patients are among the key growth drivers for the regional market growth.
Germany is currently the leading country representing the top five EU markets. Over the forecast period, the markets in the United Kingdom, Italy, and France are expected to rise moderately.
Segments
The global myeloproliferative disorders market has been segmented on the basis of
Indications
- Ph+ Chronic Myelogenous Leukemia (CML)
- Ph- Myeloproliferative Neoplasms (MPNs)
- Myelofibrosis (MF)
- Polycythemia Vera (PV)
- Essential Thrombocythemia (ET)
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Novartis AG
- Bristol-Myers Squibb Company
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Incyte Corporation
- Teva Pharmaceutical Industries Ltd.
Competitive Landscape
Key players competing in the global myeloproliferative disorders market share are Novartis AG; Bristol-Myers Squibb Company; Pfizer Inc.; Takeda Pharmaceutical Company Limited; Incyte Corporation; and Teva Pharmaceutical Industries Ltd. These companies adopted several primary strategic endeavours such as development collaborations, bigger product portfolios, and regional expansion in new markets to boost their market share.
Gleevec, a low-cost generic producer, has planned to catch on quickly and become the most common first-line treatment for CML. Incyte has a first-mover advantage over competitors for pipeline medicines as it is the sole medication approved for MF and PV for refractory patients. For Jakafi intolerant or resistant patients, novel pipeline medicines targeting the MF indication are expected to be employed.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Myeloproliferative Disorders Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Myeloproliferative Disorders Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Myeloproliferative Disorders Drugs Market - Supply Chain
4.5. Global Myeloproliferative Disorders Drugs Market Forecast
4.5.1. Myeloproliferative Disorders Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Myeloproliferative Disorders Drugs Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Myeloproliferative Disorders Drugs Market Absolute $ Opportunity
5. Global Myeloproliferative Disorders Drugs Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Myeloproliferative Disorders Drugs Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Myeloproliferative Disorders Drugs Demand Share Forecast, 2019-2026
6. North America Myeloproliferative Disorders Drugs Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Myeloproliferative Disorders Drugs Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Myeloproliferative Disorders Drugs Demand Share Forecast, 2019-2026
7. Latin America Myeloproliferative Disorders Drugs Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Myeloproliferative Disorders Drugs Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Myeloproliferative Disorders Drugs Demand Share Forecast, 2019-2026
8. Europe Myeloproliferative Disorders Drugs Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Myeloproliferative Disorders Drugs Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Myeloproliferative Disorders Drugs Demand Share Forecast, 2019-2026
9. Asia Pacific Myeloproliferative Disorders Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Myeloproliferative Disorders Drugs Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Myeloproliferative Disorders Drugs Demand Share Forecast, 2019-2026
10. Middle East & Africa Myeloproliferative Disorders Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Myeloproliferative Disorders Drugs Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Myeloproliferative Disorders Drugs Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Myeloproliferative Disorders Drugs Market: Market Share Analysis
11.2. Myeloproliferative Disorders Drugs Distributors and Customers
11.3. Myeloproliferative Disorders Drugs Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. Novartis AG Bristol-Myers Squibb Company Pfizer Inc. Takeda Pharmaceutical Company Limited Incyte Corporation Teva Pharmaceutical Industries Ltd.
Methodology
Related Reports
Some other reports from this category!
Our Clients
